home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.020 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Brinker International Posts Upbeat Results, Joins F5, T-Mobile US, Starbucks And Other Big Stocks Moving Higher On Wednesday ↗

January 29, 2025

Via Benzinga

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

January 29, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

January 27, 2025

From ImmunityBio, Inc.

Via Business Wire

Top 2 Health Care Stocks That May Fall Off A Cliff This Month ↗

October 25, 2024

Via Benzinga

IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗

January 19, 2025

Explore this week's top-performing mid-cap stocks, including H&E Equipment Services' impressive 100.59% surge following an acquisition announcement by United Rentals. Discover why stocks like SEMrush...

Via Benzinga

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details ↗

January 16, 2025

ImmunityBio advances NMIBC and NSCLC treatments with promising trial data and plans 2025 FDA submissions for innovative cancer therapies.

Via Benzinga

Symbotic, DouYu International, Sezzle And Other Big Stocks Moving Higher On Thursday ↗

January 16, 2025

Via Benzinga

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

January 15, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

January 15, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

January 06, 2025

From ImmunityBio, Inc.

Via Business Wire

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

December 12, 2024

From D. Boral Capital

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 11, 2024

Via Benzinga

What's Going On With ImmunityBio Shares Wednesday? ↗

December 11, 2024

ImmunityBio shares are trading lower on Wednesday following the announcement of pricing details for its recent $100 million share offering.

Via Benzinga

Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

December 11, 2024

Via Benzinga

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

December 11, 2024

From ImmunityBio, Inc.

Via Business Wire

Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket ↗

December 11, 2024

Via Benzinga

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

December 10, 2024

From ImmunityBio, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 29, 2024

Via Benzinga

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

November 19, 2024

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports Third-Quarter 2024 Financial Results

November 12, 2024

From ImmunityBio, Inc.

Via Business Wire

IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 30, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

October 28, 2024

Via Benzinga

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

October 28, 2024

Via Benzinga

Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio? ↗

October 27, 2024

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?

Via Benzinga

Topics Government

Jeff Bezos Ends Washington Post's 36-Year Tradition Of Endorsements, Leaving Staff 'Roiled' ↗

October 25, 2024

The Washington Post is not endorsing a candidate in a presidential election for the first time since 1988. Sources say the decision came from Jeff Bezos.

Via Benzinga

Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday ↗

October 25, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 25, 2024

Via Benzinga

Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

October 25, 2024

Via Benzinga

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

October 24, 2024

From ImmunityBio, Inc.

Via Business Wire

800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio ↗

October 23, 2024

EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com